Here's a billion-dollar idea: help people breathe better while they sleep. That's the bet Prestige Consumer Healthcare Inc. (PBH) is making, announcing a definitive agreement to acquire the iconic Breathe Right brand for a cool $1.045 billion.

Think of it as a major portfolio expansion. Prestige, known for its stable of consumer health brands, is using this deal to push into the sleep and better-breathing categories, where demand is apparently on the rise. The famous drug-free nasal strips are the headline act, but the deal also brings in other established names, including the children's cough and cold treatment brand Dimetapp.

Management is pretty optimistic about the math. They expect the acquisition to boost gross and EBITDA margins, increase free cash flow, and help support the company's long-term leverage goals. To pay for it, Prestige plans to use cash on hand and tap a new term loan facility. The company reported having $62.37 million in cash and equivalents as of December 31, 2025, so the loan is doing the heavy lifting. The whole transaction is expected to wrap up in the first half of fiscal 2027, assuming regulators give it the green light.

Now, if you're looking at the stock chart and thinking this sounds like a vote of confidence, the market's recent reaction might seem a bit... congested. The shares fell 1.14% to close at $60.06 on Thursday. A look under the technical hood shows some short-term weakness: the stock is trading 9.1% below its 20-day simple moving average and 7.6% below its 100-day average. Over the past 12 months, it's been a rough ride, with shares down 28.81%, putting the stock much closer to its 52-week low than its high.

The technical indicators are sending mixed signals. The Relative Strength Index (RSI) is at 30.25, which is in neutral territory. Meanwhile, the Moving Average Convergence Divergence (MACD) is negative at -1.54, sitting below its signal line of -0.65, which points to ongoing bearish pressure. Analysts watching the charts note key resistance at $66.00 and support near $57.50, suggesting the potential for some volatility in the near term.

Looking ahead, the next major event for the stock is likely the estimated earnings report on May 7, 2026. Expectations are for an earnings per share (EPS) of $1.41, up from $1.32, and revenue of $294.86 million, up from $276.99 million. At a price-to-earnings (P/E) ratio of 15.8x, the stock is seen as fairly valued.

The analyst consensus still leans positive, with a Buy rating and an average price target of $77.78. However, recent actions show some caution. Jefferies maintained a Hold rating but lowered its price target to $66.00 on February 2. Back in November, Canaccord Genuity reiterated a Buy but lowered its target to $88.00, and Jefferies had previously cut its target to $71.00 in late October.

For ETF investors, Prestige Consumer Healthcare is a name to know in a couple of funds. It has a 3.92% weight in the SPDR S&P Pharmaceuticals ETF (XPH) and a 2.64% weight in the Schwab Ariel ESG ETF (SAEF). What that means is pretty straightforward: significant money moving into or out of these ETFs can force automatic buying or selling of PBH shares, adding another layer to its price movements.

So, in summary: Prestige is making a huge, strategic acquisition to help you breathe easier. Whether that will help its shareholders breathe easier too remains the billion-dollar question. The deal looks smart on paper for the long-term portfolio, but the stock itself is currently dealing with some short-term headwinds.